Electroretinographic Responses in Retinopathy of Prematurity Treated Using Intravitreal Bevacizumab or Laser.
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
24
10
2022
revised:
22
04
2023
accepted:
24
04
2023
pmc-release:
01
08
2024
medline:
17
7
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
Intravitreal injection of bevacizumab (IVB) offers advantages over laser photoablation for treatment of type 1 retinopathy of prematurity (ROP). However, retinal function has not, to date, been quantitatively compared following these interventions. Therefore, electroretinography (ERG) was used compare retinal function among eyes treated using IVB or laser, and control eyes. In addition, among the IVB-treated eyes, ERG was used to compare function in individuals in whom subsequent laser was and was not required. Prospective clinical cohort study. ERG was used to record dark- and light-adapted stimulus/response functions in 21 children treated using IVB (12 of whom required subsequent laser in at least 1 eye for persistent avascular retina [PAR]). Sensitivity and amplitude parameters were derived from the a-wave, b-wave, and oscillatory potentials (OPs), representing activity in photoreceptor, postreceptor, and inner retinal cells, respectively. These parameters were then referenced to those of 76 healthy, term-born controls and compared to those of 10 children treated using laser only. In children with treated ROP, every ERG parameter was significantly below the mean in controls. However, these significant ERG deficits did not differ between IVB- and laser-treated eyes. Among children treated using IVB, no ERG parameter was significantly associated with dose or need for subsequent laser. Retinal function was significantly impaired in treated ROP eyes. Function in IVB-treated eyes did not differ from that in laser-treated eyes. Functional differences also did not distinguish those IVB-treated eyes that would subsequently need laser for PAR.
Identifiants
pubmed: 37146743
pii: S0002-9394(23)00189-7
doi: 10.1016/j.ajo.2023.04.014
pmc: PMC10524994
mid: NIHMS1899591
pii:
doi:
Substances chimiques
Bevacizumab
2S9ZZM9Q9V
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-285Subventions
Organisme : NICHD NIH HHS
ID : P50 HD105351
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY010597
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
JAMA Ophthalmol. 2014 Nov;132(11):1327-33
pubmed: 25103848
Retina. 2015 May;35(5):1007-15
pubmed: 25627091
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):453-7
pubmed: 18172125
Exp Eye Res. 1961 Sep;1:14-24
pubmed: 13871106
Development. 2006 Jun;133(11):2201-10
pubmed: 16672338
Am J Ophthalmol. 2012 Feb;153(2):327-333.e1
pubmed: 21930258
Mol Vis. 2008;14:2499-508
pubmed: 19112532
Vision Res. 1978;18(7):793-800
pubmed: 676087
Arch Ophthalmol. 2007 Nov;125(11):1581-2
pubmed: 17998528
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5199-207
pubmed: 19036998
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4351-9
pubmed: 17724227
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2814-23
pubmed: 17525217
N Engl J Med. 2011 Feb 17;364(7):603-15
pubmed: 21323540
Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5788-97
pubmed: 18055833
Prog Retin Eye Res. 2009 Nov;28(6):452-82
pubmed: 19563909
PLoS One. 2008;3(11):e3554
pubmed: 18978936
Invest Ophthalmol Vis Sci. 2015 Jan 20;56(2):914-7
pubmed: 25604681
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11946-50
pubmed: 12181492
J Physiol. 1992 Apr;449:719-58
pubmed: 1326052
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Doc Ophthalmol. 2022 Jun;144(3):165-177
pubmed: 35511377
Doc Ophthalmol. 2016 Apr;132(2):101-9
pubmed: 26996188
Br J Ophthalmol. 2006 Apr;90(4):456-60
pubmed: 16547327
Transl Vis Sci Technol. 2021 Apr 1;10(4):14
pubmed: 34003992
Ophthalmologica. 2015;234(4):211-7
pubmed: 26393895
J Physiol. 1999 Jul 15;518 ( Pt 2):479-96
pubmed: 10381594
Arch Ophthalmol. 2003 Dec;121(12):1684-94
pubmed: 14662586
J Comp Neurol. 2003 Sep 8;464(1):1-16
pubmed: 12866125
Pediatr Res. 1994 Dec;36(6):724-31
pubmed: 7898981
Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50
pubmed: 15747762
Vision Res. 2001 Apr;41(8):1091-101
pubmed: 11301082
Doc Ophthalmol. 1999;99(1):69-82
pubmed: 10947010
Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2639-47
pubmed: 16723481
Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1878-83
pubmed: 10393065
JAMA Pediatr. 2018 Mar 1;172(3):278-286
pubmed: 29309486
J Comp Neurol. 1990 Feb 22;292(4):497-523
pubmed: 2324310
Biochim Biophys Acta. 1993 Mar 1;1141(2-3):111-49
pubmed: 8382952
Invest Ophthalmol Vis Sci. 2014 Apr 29;55(5):3311-3
pubmed: 24781938
Vision Res. 1985;25(10):1365-73
pubmed: 4090272
Prog Retin Eye Res. 1998 Oct;17(4):485-521
pubmed: 9777648
Invest Ophthalmol Vis Sci. 1994 Jan;35(1):295-309
pubmed: 8300357
Doc Ophthalmol. 1992;80(4):335-45
pubmed: 1473449
Doc Ophthalmol. 1998-1999;95(3-4):187-215
pubmed: 10532405
Prog Retin Eye Res. 2017 Jan;56:32-57
pubmed: 27671171
Exp Eye Res. 2019 Dec;189:107827
pubmed: 31600486
Vis Neurosci. 1995 Sep-Oct;12(5):837-50
pubmed: 8924408
Invest Ophthalmol Vis Sci. 2000 May;41(6):1588-96
pubmed: 10798680
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):814-9
pubmed: 18235032
Br J Ophthalmol. 1997 Jan;81(1):2-3
pubmed: 9135397
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):320-4
pubmed: 10634637
Sci Rep. 2015 Dec 16;5:18316
pubmed: 26671074
Pediatrics. 2016 Apr;137(4):
pubmed: 27244705
J Neurosci. 2000 Sep 15;20(18):6781-8
pubmed: 10995821
J Ophthalmol. 2017;2017:4353129
pubmed: 28770109
Ophthalmology. 1984 Jun;91(6):603-12
pubmed: 6462623
Invest Ophthalmol Vis Sci. 1994 Jun;35(7):2948-61
pubmed: 8206712
Am J Ophthalmol. 2022 Aug;240:252-259
pubmed: 35367438
Arch Ophthalmol. 2011 Feb;129(2):127-32
pubmed: 21320954
Invest Ophthalmol Vis Sci. 2013 Dec 19;54(13):8275-84
pubmed: 24168993
Acta Ophthalmol Suppl (1985). 1992;(204):10-5
pubmed: 1332382
PLoS One. 2019 Dec 2;14(12):e0225643
pubmed: 31790445
Doc Ophthalmol. 2011 Feb;122(1):19-27
pubmed: 21046193
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):168-74
pubmed: 9888440
Vis Neurosci. 1994 May-Jun;11(3):519-32
pubmed: 8038126
Surv Ophthalmol. 2008 Jan-Feb;53(1):16-40
pubmed: 18191655
Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3458-62
pubmed: 16123452